In simple terms the Neuren product is a more generic treatment which acts on the inflammation that is the end product of the Shank 3 mutation. Our product is aimed at stopping the process at its source the Shank3 protein.
In theory ours is a more elegant solution. In practise I suspect they will work well together in combination as they work on different parts of the disease process.
Time will tell. I don’t know if this will affect orphan disease status or not.
In simple terms the Neuren product is a more generic treatment...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.010(10.0%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 11.0¢ | 11.0¢ | 10.0¢ | $430.2K | 4.019M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 227514 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 1209313 | 12 |
View Market Depth
| Last trade - 16.10pm 07/06/2024 (20 minute delay) ? |
|
|||||
|
Last
11.0¢ |
Change
0.010 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 11.0¢ | 10.3¢ | 2812759 | ||
| Last updated 15.29pm 07/06/2024 ? | |||||
| PYC (ASX) Chart |